Advertisement

Topics

Onxeo S.A. Company Profile

18:24 EDT 17th June 2018 | BioPortfolio

Onxeo has the vision to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, through developing innovative therapeutic alternatives to “make the difference”. The Onxeo teams are determined to develop innovative medicines to provide patients with hope and significantly improve their lives.


News Articles [17 Associated News Articles listed on BioPortfolio]

Onxeo Announces Its Financial Agenda For 2018

Regulatory News: Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO) (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), ("Onxeo" or the "Company"), a biotechnology company specializing in the develo...

Onxeo to Attend Key Investor and Partnering Conferences in H1 2018

Regulatory News: Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), ("Onxeo" or the "Company"), a biotechnology company specializing in the development of innovative drugs in onco...

Onxeo Provides Financial Update

Regulatory News: Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company specializing in the development of innovative drugs in oncology, and notably rare and r...

Onxeo S.A.: Publication of 2017 Registration Document

Regulatory News: Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company specializing in the development of innovative drugs in oncology, in particular against ...

Onxeo S.A.: Combined General Meeting on May 16, 2018

Regulatory News: Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company specializing in the development of innovative drugs in oncology, in particular against ...

Onxeo to Present at BIO International Convention in Boston

PARIS–(BUSINESS WIRE)–Regulatory News: Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company specializing in the development of innovative drugs in on...

Onxeo (ONXEO) - Phase I with AsiDNA iv starts; first data in H218

Edison Investment Research - Pharmaceutical & healthcare - Onxeo: On 24 April, Onxeo announced that the first patient had been treated with AsiDNA, a first-in-class DNA break repair inhibitor, via sys...

Onxeo Reports Full-Year 2017 Financial Results and Provides Business Update

Advancement of core pipeline assets on track with key development catalysts expected in 2018 First new molecule generated from platON, Onxeo's proprietary development platform, to enter preclinica...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [2 Associated Companies listed on BioPortfolio]

Onxeo S.A.

Onxeo has the vision to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, through developing innovative therapeutic alternatives to “mak...

Onxeo SA

Onxeo has the vision to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, through developing innovative therapeutic alternatives to “mak...

More Information about "Onxeo S.A." on BioPortfolio

We have published hundreds of Onxeo S.A. news stories on BioPortfolio along with dozens of Onxeo S.A. Clinical Trials and PubMed Articles about Onxeo S.A. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Onxeo S.A. Companies in our database. You can also find out about relevant Onxeo S.A. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


Corporate Database Quicklinks



Searches Linking to this Company Record